Şunu aradınız:: infliksimaba (Hırvatça - İngilizce)

putevi eliminacije infliksimaba nisu opisani.
the elimination pathways for infliximab have not been characterised.

jedna bočica sadrži 100 mg infliksimaba.
each vial contains 100 mg of infliximab.

nije ispitivana farmakokinetika infliksimaba u starijih bolesnika.
the pharmacokinetics of infliximab in elderly patients has not been studied.

reakcije na infuziju nakon ponovne primjene infliksimaba
infusion reactions following re-administration of infliximab

nakon rekonstitucije jedan ml sadrži 10 mg infliksimaba.
after reconstitution each ml contains 10 mg infliximab.

nakon rekonstitucije, svaki ml sadrži 10 mg infliksimaba.
after reconstitution each ml contains 10 mg of infliximab.

jedna bočica lijeka flixabi sadrži 100 mg infliksimaba.
each flixabi vial contains 100 mg infliximab.

nakon pripreme otopine, 1 ml sadrži 10 mg infliksimaba.
after reconstitution each ml contains 10 mg infliximab.

nakon pripreme otopine, jedan ml sadrži 10 mg infliksimaba.
after preparation each ml contains 10 mg of infliximab

nisu provedena dugotrajna istraživanja radi procjene kancerogenog potencijala infliksimaba.
long-term studies have not been performed to evaluate the carcinogenic potential of infliximab.

djelotvornost infliksimaba do 54. tjedna ispitivala se u ispitivanju act 1.
the efficacy of infliximab through week 54 was assessed in the act 1 study.

Čini se da kortikosteroidi nemaju klinički značajan utjecaj na farmakokinetiku infliksimaba.
corticosteroids do not appear to affect the pharmacokinetics of infliximab to a clinically relevant extent.

bolesnici su primili tri doze placeba ili infliksimaba u 0., 2. i 6. tjednu.
patients received three doses of either placebo or infliximab at weeks 0, 2 and 6.

od tih 108 bolesnika, 27 je liječeno preporučenom dozom infliksimaba od 5 mg/kg.
of these 108 patients, 27 were treated with the recommended dosage of infliximab 5 mg/kg.

kliničko iskustvo je premalo za isključivanje rizika te se stoga ne preporučuje primjena infliksimaba u trudnoći.
the available clinical experience is too limited to exclude a risk, and administration of infliximab is therefore not recommended during pregnancy.

budući da inhibira tnfα, primjena infliksimaba tijekom trudnoće može utjecati na normalan imunološki odgovor novorođenčeta.
due to its inhibition of tnfα, infliximab administered during pregnancy could affect normal immune responses in the newborn.

budući da eliminacija infliksimaba može potrajati i do 6 mjeseci, bolesnik mora biti pod nadzorom i tijekom tog razdoblja.
because the elimination of infliximab may take up to six months, monitoring should be continued throughout this period.

broj kirurških zahvata zbog ulceroznog kolitisa također je bio manji u skupinama koje su primale dozu infliksimaba od 5 mg/kg odnosno
the number of ulcerative colitis-related surgical procedures was also lower in the

djelotvornost infliksimaba ispitivana je u dva multicentrična, randomizirana, dvostruko slijepa, ispitivanja: spirit i express.
the efficacy of infliximab was assessed in two multicentre, randomised, double-blind studies: spirit and express.

djelotvornost i sigurnost primjene infliksimaba ispitivane su u dva multicentrična, dvostruko slijepa, placebom kontrolirana ispitivanja u bolesnika s aktivnim psorijatičnim artritisom.
efficacy and safety were assessed in two multicentre, double-blind, placebo-controlled studies in patients with active psoriatic arthritis.